2 sources
Seeking Alpha (US)2h ago
Novo Nordisk licenses Hengrui’s obesity drug HRS-1596 in a deal up to $2.6B—see key terms, regions excluded, and what it means for investors.
OriginalThe Business Times4h ago
China signals economic stimulus to counter worsening slowdown - businesstimes.com.sg
Original